Pharma Leadership & Organization Model
Zambon S.p.A. Board
Strategic Advisory Board
Roberto Tascione, CEO of Zambon S.p.A. since September 2016, has been guiding the company’s business on a global scale. Under his leadership, Zambon S.p.A. has focused its resources on specific therapeutic areas and core brands, achieving constant growth in Europe and South America and exponential growth in high-potential markets, such as China. He also successfully extended the launch of Safinamide for Parkinson's disease to 5 continents.
He initiated new research programs, tripled investments, and built a robust pipeline in specialties, which consolidated the company as a pioneer in the development of therapies for rare severe respiratory diseases, today with no cure, such as Non-Cystic Fibrosis Bronchiectasis (NCFB). In 2019, he finalized the acquisition of Breath Therapeutics, adding to the pipeline a potential Phase 3 development treatment for Bronchiolitis Obliterans (BOS), for which there is no approved treatment worldwide.
Roberto brought to Zambon 30 years of experience in multinational pharmaceutical companies, covering C-level positions with significant international exposure. He began his career at Bristol Myers Squibb. In 2004 he became Director of the Primary Care and OTC Units at Schering-Plough and, subsequently, in 2009, he was appointed President and CEO of Gilead Italy. In 2014, he returned to Bristol Myers Squibb as President and CEO Italy.
During the years at Gilead and Bristol Myers Squibb, he contributed to the arrival and success in Italy of some of the most important and revolutionary drugs in the treatment of HIV / AIDS, hepatitis C, cardiovascular diseases, and in the immuno-oncology field.
Roberto was a member of the General Council of Confindustria and the Council and Supervisory Board of Ethical Code in Farmindustria. He graduated with Honors in Pharmacy at the University of Bologna.
Luca Benatti is the Chief Executive Officer of EryDel. He has over 25 years’ experience in Pharma and Biotech. He was co-founder and CEO of Newron Pharmaceuticals (NWRN, Swiss Stock Exchange). Under his guidance, Newron developed a pipeline of innovative therapies including Xadago, approved worldwide for the treatment of Parkinson's disease.
He is board member at Intercept Pharmaceuticals (ICPT, Nasdaq), NewronPharmaceuticals, Chairman of the Italian Angels for Biotech, Member of the Board of Assobiotec, Member of the Jury of the European Biotechnica Award and of the Open Accelerator Award. Luca has also authored several scientific publications and holds numerous patents.
Giovanni Cagnoli is the President of Carisma SpA. He founded Bain & Company Italy in 1989. Under his long-time leadership as CEO, Bain & Company Italy has achieved a significant and prestigious positioning in the market. Giovanni was an active part in developing and supporting some of the most important public and private Italian companies, in setting and reaching ambitious objectives across industries and targets for almost 30 years. He has a key and unique experience in business strategy development, in merger and acquisition’s management.
Giovanni holds an MBA from Sloan School of Management at M.I.T. in Boston and a Business Administration degree from Bocconi University in Milan.
Paul Carter is former EVP and worldwide commercial head at Gilead Sciences Inc. Previously he was head of Europe and International markets for Gilead. During this time, he was responsible for launching and growing several major products including four of the top ten most successful products in US and European Biopharma history as measured by first year revenues. He was also responsible for building out Gilead’s commercial infrastructure in Europe, Japan and several other important markets in Asia and Latin America. Paul is now on the Board of Directors of several US listed Biopharma companies. He is also a retained advisor to Private Equity, Digital and other service providers to the Life Science space. Prior to Gilead, Paul had a 15-year career of increasing responsibilities at GSK and its legacy companies. This included being Regional Head of China and various General Manager positions in Europe and Asia.
Giacomo Di Nepi brings over 35 years of experience in the pharma and biotech industries. He is Senior Advisor for KKR (NYSE: KKR), focusing on Healthcare Private Equity Europe, and Chairman or Board Member for Peptomyc, Geneuro (Euronext: GNRO.PA) and NTC. He is also Senior Advisor for Handicap International in Geneva. Prior, Giacomo was CEO of Polyphor (SIX: POLN), where he brought two products to Phase III and led a CHF 155M IPO – the largest biopharma IPO in Switzerland in the previous 10 years. He was Head of Europe for InterMune (NASDAQ: ITMN), where he started up the EU operation and successfully launched and grew the first IPF drug, until the acquisition from Roche for USD 8.3B, and was CEO for Takeda Europe. In addition, he covered several leadership roles in Novartis – most recently as Member of the Pharma Executive Committee and Head for the Transplant, Immunology, and Infectious Diseases Global Business Unit, and was a Partner and Core Pharma Practice member with McKinsey&Co. He holds a degree in Economics from Bocconi University and an MBA from INSEAD. He worked and lived in Italy, Switzerland, US, UK, and France.
Guido Guidi has an experience of over 35 years in the pharma industry and today he’s a senior consultant and member of different boards of pharmaceutical and diagnostic companies. Previously Guido had a long career in Novartis where he set up the whole business for Oncology Europe and then became Head of Pharma Region Europe. In this position, he was responsible for leading the General Medicines Business in the European Region, marketing several key products and coordinating the Pharma operations of RE countries. He has been instrumental in creating a visionary collaborative approach as well as a pioneer in leading the company towards patient centricity, setting a new path for the industry. He holds a degree cum laude in Medicine and Specialization in Immunology and Rheumatology at University of Milan. He contributed to around 30 publications, mainly focusing on methodologies and management of clinical research.
Executive Management Committee
We have set up a team of professionals able to lead our business worldwide and to catch all the present challenges and opportunities. Thanks to their international experience, innovative approach and positive track record, we have the ambition to make the difference every day.